Replies to post #685153 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

The problem with a statement like the improvement is 3+ months, that's where the survivors hit the 50% point. What would the benefit be if you took all the patients at the current point in their lives. I suspect that there are people who were some of the first in the trial who're still alive, many with 10 years or more. I think that longevity is far more important than when we went below 50% surviving. If we took the average life span of all the patients it would still be growing as many of them just keep adding years.

Gary

[biosectinvestor]

If you can read like everyone else, why exactly are you presenting patently false information? You can’t read apparently or you lied.

The company clearly reported their result and the difference and the fact that it is a significant benefit for virtually all patients generally and there are specific groups of patients who did incredibly better than the median. By a lot. And subsequent studies are showing that with combinations to address secondary immune responses that typically happen because the body misidentifies an immune response as an autoimmune response, or because the immune response is not as vigorous though the right targets are identified. These methods of action are cumulative and are being addressed with the relevant drugs that are already approved that will enable what looks like it could be an incredibly strong and broad immune response from the pending paper with possibly Nature.

In fact, in a key arm, as you know. 100% of the patients are still living, all over 9 years of 4, and 3 of those over 10 years, all still alive, last we heard. Not GBM, but serious brain tumors for which shorter terms of survival are typical.

As multiple survey papers have suggested as well as the JAMA paper, there is no reasonable alternative suggestion for the increased survival though our resident shorts like to argue that larger tumors that can require surgery are “better”…